Skip to content
http://lifestyle.lmcordoba.com.ar/
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
CASI Pharmaceuticals
CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel
February 25, 2026
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)
January 15, 2026
CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
January 12, 2026
CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
December 23, 2025